Hikma Pharmaceuticals PLC (LON:HIK)
London · Delayed Price · Currency is GBP · Price in GBX 1,636.00
+12.00 (0.74%)
Aug 21, 2026, 4:35 PM GMT
Hikma Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,419 | 3,349 | 3,127 | 2,875 | 2,517 | 2,553 | |
Revenue Growth | 6.31% | 7.10% | 8.77% | 14.22% | -1.41% | 9.06% |
Cost of Revenue | 1,913 | 1,892 | 1,708 | 1,468 | 1,252 | 1,252 |
Gross Profit | 1,506 | 1,457 | 1,419 | 1,407 | 1,265 | 1,301 |
Selling, General & Admin | 670 | 666 | 660 | 632 | 601 | 561 |
Research & Development | 164 | 151 | 141 | 149 | 144 | 143 |
Other Operating Expenses | -8 | -8 | 4 | 1 | 22 | 36 |
Operating Expenses | 826 | 809 | 805 | 782 | 767 | 740 |
Operating Income | 680 | 648 | 614 | 625 | 498 | 561 |
Interest Expense | -97 | -85 | -75 | -73 | -59 | -43 |
Interest & Investment Income | 5 | 6 | 8 | 7 | 3 | 1 |
Earnings From Equity Investments | - | - | 1 | - | - | 1 |
Currency Exchange Gain (Loss) | -11 | -11 | -21 | -9 | -7 | - |
Other Non Operating Income (Expenses) | -12 | -12 | -13 | -14 | -11 | -13 |
EBT Excluding Unusual Items | 565 | 546 | 514 | 536 | 424 | 507 |
Merger & Restructuring Charges | -20 | -21 | -15 | - | -41 | - |
Gain (Loss) on Sale of Investments | - | 1 | 1 | 2 | -2 | - |
Gain (Loss) on Sale of Assets | - | - | - | - | 12 | -1 |
Asset Writedown | -36 | -26 | 29 | -85 | -182 | 22 |
Legal Settlements | - | -72 | - | -129 | - | - |
Other Unusual Items | 2 | 77 | -74 | -43 | 22 | 16 |
Pretax Income | 511 | 519 | 455 | 281 | 233 | 544 |
Income Tax Expense | 119 | 112 | 93 | 89 | 42 | 124 |
Earnings From Continuing Operations | 392 | 407 | 362 | 192 | 191 | 420 |
Minority Interest in Earnings | -5 | -5 | -3 | -2 | -3 | 1 |
Net Income | 387 | 402 | 359 | 190 | 188 | 421 |
Net Income to Common | 387 | 402 | 359 | 190 | 188 | 421 |
Net Income Growth | 4.31% | 11.98% | 88.95% | 1.06% | -55.34% | -2.32% |
Shares Outstanding (Basic) | 219 | 221 | 221 | 221 | 224 | 231 |
Shares Outstanding (Diluted) | 221 | 223 | 223 | 222 | 225 | 233 |
Shares Change | -0.92% | -0.36% | 0.51% | -1.13% | -3.47% | -2.10% |
EPS (Basic) | 1.77 | 1.82 | 1.62 | 0.86 | 0.84 | 1.82 |
EPS (Diluted) | 1.76 | 1.81 | 1.61 | 0.85 | 0.84 | 1.81 |
EPS Growth | 5.33% | 12.42% | 89.41% | 1.19% | -53.51% | -0.22% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 238 | 239 | 399 | 439 | 392 | 493 |
Free Cash Flow Per Share | 1.08 | 1.07 | 1.78 | 1.97 | 1.74 | 2.12 |
Dividend Per Share | 0.860 | 0.840 | 0.800 | 0.720 | 0.560 | 0.540 |
Dividend Growth | 2.38% | 5.00% | 11.11% | 28.57% | 3.70% | 8.00% |
Gross Margin | 44.05% | 43.51% | 45.38% | 48.94% | 50.26% | 50.96% |
Operating Margin | 19.89% | 19.35% | 19.63% | 21.74% | 19.79% | 21.97% |
Profit Margin | 11.32% | 12.00% | 11.48% | 6.61% | 7.47% | 16.49% |
Free Cash Flow Margin | 6.96% | 7.14% | 12.76% | 15.27% | 15.57% | 19.31% |
EBITDA | 879 | 842 | 793 | 797 | 670 | 718 |
EBITDA Margin | 25.71% | 25.14% | 25.36% | 27.72% | 26.62% | 28.12% |
D&A For EBITDA | 199 | 194 | 179 | 172 | 172 | 157 |
EBIT | 680 | 648 | 614 | 625 | 498 | 561 |
EBIT Margin | 19.89% | 19.35% | 19.63% | 21.74% | 19.79% | 21.97% |
Effective Tax Rate | 23.29% | 21.58% | 20.44% | 31.67% | 18.03% | 22.79% |